IBAB Ion Beam Applications SA

IBA and TRAD Tests & Radiations announce collaboration to develop next generation radiation processing application

IBA and TRAD Tests & Radiations announce collaboration to develop next generation radiation processing application

Long-term strategic partnership to facilitate the transition to E-beam and X-ray sterilization

Louvain-la-Neuve (Belgium) and Labege (France), 28 October 2021 – IBA (Ion Beam Applications S.A) and TRAD Tests & Radiations (SARL TRAD), today announced a strategic partnership to enable the development of a new radiation processing module based on TRAD’s RayXpert® 3D modelling and dose calculation technology.  

RayXpert®, a 3D modelling and dose calculation software that uses the Monte Carlo calculation method, is currently used for nuclear and medical applications. It is the only dose calculation software that combines the simplicity and speed of use with the high level of accuracy of the Monte Carlo method.

IBA and TRAD will expand RayXpert® capabilities by designing a new module that will make it easier to validate newly developed products that use cutting-edge electron beam (E-beam) and X-ray technology. Such technology can be used for various industrial applications, including sterilization of Disposable Medical Devices (DMD).

IBA is a world leader in E-beam and X-ray sterilization and, with TRAD’s simulation expertise, the two companies will leverage their capabilities to develop innovative solutions in sterilization and optimize radiation processing. The partnership will cover the R&D, marketing and sales aspects of the new RayXpert® module.

Thomas Servais, President of IBA Industrial, commented, “We are excited to be partnering with TRAD. Their expertise in the development of first-in-class software specifically dedicated to the nuclear sector, combined with IBA’s extensive experience in the radiation processing market, will enable us to bridge the gap between the current technology and the increasing unmet need in the sterilization market.”

“IBA is the undisputed leader in X-ray and E-beam technologies and we look forward to collaborating with them to improve the industrial method in radiation processing and develop the application of simulation with RayXpert® for the benefit of sterilization.” said Christian Chatry, President of TRAD.

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,500 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:   - -industrial.com

About TRAD

Founded in 1994, TRAD Tests & Radiation is an independent company providing a high level of service for all radiation testing, calculation and analysis services. Its core business is the testing and analysis of radiation effects on materials, components and electronic systems, as well as the development and marketing of radiation calculation and simulation software dedicated to the Space, Nuclear and Medical sectors.

More information can be found at: and

For further information, please contact:

IBA                                                                 TRAD Tests & Radiations

Olivier Lechien                                               Christian Chatry

Corporate Communication Director              President

                                             60

                   

Attachment



EN
28/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE

IBA – TRANSPARENCY NOTIFICATION

IBA – TRANSPARENCY NOTIFICATION (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, November 12th, 2025 06:00 PM Summary of the notification IBA SA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on November 7th, 2025. In its notification, IBA SA indicated...

 PRESS RELEASE

IBA SA – NOTIFICATION TRANSPARENCE

IBA SA – NOTIFICATION TRANSPARENCE (article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 12 novembre 2025, 18:00 Résumé de la notification IBA SA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce devoir effectuer une notification en matière de transparence conformément à l'article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes (« loi transparence »), à la suite d’une notification re...

 PRESS RELEASE

IBA – Regulated information

IBA – Regulated information                                                                                                                   November 7th, 2025 Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions (Belgian Gazette 12.VI.2007) (hereinafter, the “Law”). Under this provision:  « [...] the issuer publishes the total capital, the total number of securities conferring the right to vote and voting rights, as well as, by cate...

 PRESS RELEASE

IBA – Information Réglementée

IBA – Information Réglementée 7 novembre 2025 Publication effectuée en vertu de l’article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et portant des dispositions diverses (M.B. 12.VI.2007) (ci-après, la « Loi »). En vertu de cette disposition : « [...] l'émetteur publie le total du capital, le nombre total de titres conférant le droit de vote et de droits de vote, ainsi que, par catégorie, le nombre de titres conférant le droit de vote et de droits de vote, au ...

 PRESS RELEASE

IBA integrates Artificial Intelligence Quality Assurance into dosimetr...

IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH Dosimetry portfolio strengthened with Medical Imaging QA and AI validation  Louvain-la-Neuve, Belgium, 03 November 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of quality assurance (QA) solutions, today announces the acquisition of PhantomX GmbH, expanding IBA’s portfolio in healthcare diagnostics and therapeutic systems enabling artificial intelligence (AI) quality assurance. Found...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch